vTv Therapeutics Shortens Type 1 Diabetes Trial, Aims for Faster Results with Protocol Amendment
vTv Therapeutics Inc. has accelerated its Type 1 Diabetes trial, CATT1, with a protocol amendment, aiming to bring a new treatment option to market more swiftly.
2 minutes to read